
CPHI Milan 2026: Molecule First, Patient Always - Chris Davison
Register your interest for 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto
Centrix Pharma Solutions helps biotech companies move from preclinical development into early stage clinical development. For CEO Chris Davison, that means the molecule first and the patient always: "we don't just make a product, we make medicines."
This week on Making It In Manufacturing, Harry Sloan sat down with Chris Davison, CEO of Centrix Pharma Solutions, a small CDMO based in the UK, at CPHI Milan 2026, where ARTO was the official podcast partner.
In this episode, Chris covers:
(00:57) What Centrix does: formulation, analytical work and clinical manufacturing for biotech companies heading into the clinic, and what "Molecule First, Patient Always" means in practice.
(02:23) His path to CEO: a pharmacist by training, 23 years at GSK in pharmaceutical development and leading CMC teams, then manufacturing supply chain and launches, before moving to Custom Pharmaceuticals and stepping up to lead the business.
(04:03) Going from big pharma to a small company: wearing multiple hats, relying on your network, and not being afraid to ask for help.
(05:16) Why now was the time to launch Centrix out of Custom Pharmaceuticals, a business that has been around for 47 years, and why it helps clients with what they need today and what they will need tomorrow.
(07:23) Partnership, not transactions: challenging small biotechs on the consequences of their decisions down the line, so they make them with their eyes wide open.
(09:41) The Integrated CMC Partnership with Sai Life Sciences and Agility Life Sciences, built to take the handoff out between drug substance and drug product.
(12:28) Backing the growth plans: equipment that gives very rich data from small amounts of material, and an Innovate UK knowledge transfer partnership with the University of Sussex that brings a data scientist into the business.
(15:05) What growth depends on: clients, the funding bar for biotech, and talent, with recent recruits from Brighton University, and why the people in a business drive its credibility.
(18:12) How biotechs now choose a development partner: shorter runways, more selective, and wanting help to navigate their own journey rather than just a formulation and a batch.
(19:09) Where AI fits at Centrix today: models to inform drug development, help in the quality functions with the human still at the centre, and empowering the workforce rather than replacing it.
(21:40) What he wants Centrix to have delivered a year from now.
Watch the full episode to hear why Chris wants more people to know what it really takes to develop a product.
Follow ARTO
LinkedIn: https://www.linkedin.com/company/artotalent/
Spotify: https://open.spotify.com/show/1cSZVJ63yXJ3kqnVORyTbw
Instagram: https://www.instagram.com/arto.talent
TikTok: https://www.tiktok.com/@artotalent
Apple Podcasts: https://podcasts.apple.com/gb/podcast/making-it-in-manufacturing/id1819731245
Website: https://arto-talent.com/
Youtube: https://www.youtube.com/@artotalent
Chris Davison
LinkedIn: https://www.linkedin.com/in/chrisdavison155/
Harry Sloan
LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/
Timestamps:
00:00 Introduction
00:57 What Centrix does
02:23 From pharmacist to CEO
04:03 Big pharma to a small company
05:16 Why launch Centrix now
07:23 Partnership, not transactions
09:41 The Integrated CMC Partnership
12:28 Investing in data and growth
15:05 What growth depends on
18:12 How biotechs choose a partner
19:09 Where AI fits today
21:40 A year from now
#MakingItInManufacturing #ARTOTalent #CPHI #CPHIMilan #CDMO #Biotech #CMC #DrugDevelopment
Hosted on Acast. See acast.com/privacy for more information.
Fler avsnitt från "Making it in Manufacturing"



Missa inte ett avsnitt av “Making it in Manufacturing” och prenumerera på det i GetPodcast-appen.








